PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability

Cancer Discovery

Volumn 7, Issue 8, 2017, Pages 884-899

  Gryder, Berkley E ^a   Yohe, Marielle E ^a   Chou, Hsien Chao ^a   Zhang, Xiaohu ^b   Marques, Joana ^c   Wachtel, Marco ^c   Schaefer, Beat ^c   Sen, Nirmalya ^a   Song, Young ^a   Gualtieri, Alberto ^d   Pomella, Silvia ^d   Rota, Rossella ^d   Cleveland, Abigail ^a   Wen, Xinyu ^a   Sindiri, Sivasish ^a   Wei, Jun S ^a   Barr, Frederic G ^a   Das, Sudipto ^e   Andresson, Thorkell ^e   Guha, Rajarshi ^b   Lal Nag, Madhu ^b   Ferrer, Marc ^b   Shern, Jack F ^a   Zhao, Keji ^f   Thomas, Craig J ^b   Khan, Javed ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^e NATIONAL CANCER INSTITUTE   (United States)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; BROMODOMAIN CONTAINING PROTEIN 4; BROMODOMAIN INHIBITOR; MYCN PROTEIN; MYOD PROTEIN; MYOG PROTEIN; MYOGENIC FACTOR; N MYC PROTO ONCOGENE PROTEIN; PAIRED BOX TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; BRD4 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN; MYOG PROTEIN, HUMAN; MYOGENIN; NUCLEAR PROTEIN; ONCOPROTEIN; PAX3-FOXO1A FUSION PROTEIN, HUMAN; PROTEIN BINDING; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; ENHANCER REGION; EPIGENETICS; GENE EXPRESSION REGULATION; HISTONE ACETYLATION; HISTONE DEMETHYLATION; MOUSE; MUSCLE DEVELOPMENT; MYCOPLASMA; NONHUMAN; PERSONALIZED MEDICINE; PROMOTER REGION; PROTEIN DNA BINDING; RHABDOMYOSARCOMA; RNA SEQUENCE; SEQUENCE ANALYSIS; TUMOR GROWTH; ADMINISTRATION AND DOSAGE; ANIMAL; CHROMATIN; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENETIC EPIGENESIS; GENETICS; HUMAN; MALE; MOLECULAR LIBRARY; PATHOLOGY; PROTEIN DOMAIN; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHROMATIN; ENHANCER ELEMENTS, GENETIC; EPIGENESIS, GENETIC; FEMALE; HUMANS; MALE; MICE; MYOD PROTEIN; MYOGENIN; N-MYC PROTO-ONCOGENE PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; PROTEIN BINDING; PROTEIN DOMAINS; RHABDOMYOSARCOMA, ALVEOLAR; SMALL MOLECULE LIBRARIES; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85026856556     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-1297     Document Type: Article

References (60)

1. Lee Tong I, Young Richard A. Transcriptional regulation and its mis-regulation in disease. Cell 2013;152:1237–51.
2. Rabbitts T. Chromosomal translocations in human cancer. Nature 1994;372:143–9.
3. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216–31.
4. Chen X, Stewart E, Shelat Anang A, Qu C, Bahrami A, Hatley M, et al. Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. Cancer Cell 2013;24:710–24.
5. Riggi N, Knoechel B, Gillespie Shawn M, Rheinbay E, Boulay G, Suvà Mario L, et al. EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in ewing sarcoma. Cancer Cell 2014;26:668–81.
6. Kadoch C, Crabtree Gerald R. Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX oncogenic fusion in synovial sarcoma. Cell 2013;153:71–85.
7. Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins; 2015.
8. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F, et al. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012;30:1670–7.
9. Khan J, Simon R, Bittner M, Chen Y, Leighton SB, Pohida T, et al. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res 1998;58:5009–13.
10. Davis RJ, Barr FG. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma. Proc Nat Acad Sci 1997;94:8047–51.
11. Davicioni E, Graf Finckenstein F, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936–46.
12. Khan J, Bittner ML, Saal LH, Teichmann U, Azorsa DO, Gooden GC, et al. cDNA microarrays detect activation of a myogenic transcription program by the PAX3–FKHR fusion oncogene. Proc Natl Acad Sci U S A 1999;96:13264–9.
13. Bid HK, Phelps DA, Xiao L, Guttridge DC, Lin J, London C, et al. The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma. Mol Cancer Ther 2016;15: 1018–28.
14. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, Emanuel BS. Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993;3:113–7.
15. Cao LA, Yu YK, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO, et al. Genome-Wide Identification of PAX3–FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010;70:6497–508.
16. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature 2015;518:317–30.
17. McLean CY, Bristor D, Hiller M, Clarke SL, Schaar BT, Lowe CB, et al. GREAT improves functional interpretation of cis-regulatory regions. Nat Biotechnol 2010;28:495–501.
18. Begum S, Emani N, Cheung A, Wilkins O, Der S, Hamel PA. Cell-type-specific regulation of distinct sets of gene targets by Pax3 and Pax3// FKHR 2005;24:1860–72.
19. Rao Suhas SP, Huntley Miriam H, Durand Neva C, Stamenova Elena K, Bochkov Ivan D, Robinson James T, et al. A 3D map of the human genome at kilobase resolution reveals principles of chromatin looping. Cell 2014;159:1665–80.
20. Trapnell C, Cacchiarelli D, Grimsby J, Pokharel P, Li S, Morse M, et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotech 2014;32:381–6.
21. Tenente IM, Hayes MN, Ignatius MS, McCarthy K, Yohe M, Sindiri S, et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. eLife 2017;6:e19214.
22. Hnisz D, Abraham Brian J, Lee Tong I, Lau A, Saint-André V, Sigova Alla A, et al. Super-enhancers in the control of cell identity and disease. Cell 2013;155:934–47.
23. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 2013;153:307–19.
24. Dukler N, Gulko B, Huang Y-F, Siepel A. Is a super-enhancer greater than the sum of its parts? Nat Genet 2017;49:2–3.
25. Lin CY, Erkek S, Tong Y, Yin L, Federation AJ, Zapatka M, et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 2016;530:57–62.
26. Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987;51:987–1000.
27. Ernst J, Kheradpour P, Mikkelsen TS, Shoresh N, Ward LD, Epstein CB, et al. Mapping and analysis of chromatin state dynamics in nine human cell types. Nature 2011;473:43–9.
28. Orlando David A, Chen Mei W, Brown Victoria E, Solanki S, Choi Yoon J, Olson Eric R, et al. Quantitative ChIP-Seq normalization reveals global modulation of the epigenome. Cell Reports 2014;9:1163–70.
29. Lin Charles Y, Lovén J, Rahl Peter B, Paranal Ronald M, Burge Christopher B, Bradner James E, et al. Transcriptional amplification in tumor cells with elevated c-myc. Cell 2012;151:56–67.
30. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 2012;151:68–79.
31. Saint-André V, Federation AJ, Lin CY, Abraham BJ, Reddy J, Lee TI, et al. Models of human core transcriptional regulatory circuitries. Genome Res 2016;26:385–96.
32. Hettmer S, Wagers AJ. Muscling in: Uncovering the origins of rhabdomyosarcoma. Nat Med 2010;16:171–3.
33. Kitamura T, Feng Y, Kitamura YI, Chua SC, Xu AW, Barsh GS, et al. Forkhead protein FoxO1 mediates Agrp-dependent effects of leptin on food intake. Nature medicine 2006;12:534–40.
34. Shi J, Vakoc Christopher R. The mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. Mol Cell 2014;54: 728–36.
35. Jones LH, Bunnage ME. Applications of chemogenomic library screening in drug discovery. Nat Rev Drug Discov 2017;16:285–96.
36. Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective inhibition of BET bromodomains. Nature 2010;468: 1067–73.
37. Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discovy 2013;3:308–23.
38. Jang MK, Mochizuki K, Zhou M, Jeong H-S, Brady JN, Ozato K. The bromodomain protein Brd4 Is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005;19:523–34.
39. Lovén J, Hoke Heather A, Lin Charles Y, Lau A, Orlando David A, Vakoc Christopher R, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013;153:320–34.
40. Bradner JE, Hnisz D, Young RA. Transcriptional addiction in cancer. Cell 2017;168:629–43.
41. Roe J-S, Mercan F, Rivera K, Pappin Darryl J, Vakoc Christopher R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell 2015;58:1028–39.
42. Crose LE, Etheridge KT, Chen C, Belyea B, Talbot LJ, Bentley RC, et al. FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res 2012;18:3780–90.
43. Kim SY, Toretsky JA, Scher D, Helman LJ. The role of IGF-1R in pediatric malignancies. Oncologist 2009;14:83–91.
44. Abraham J, Nuñez-Álvarez Y, Hettmer S, Carrió E, Chen H-IH, Nishijo K, et al. Lineage of origin in rhabdomyosarcoma informs pharmacological response. Genes Deve 2014;28:1578–91.
45. Kutko MC, Glick RD, Butler LM, Coffey DC, Rifkind RA, Marks PA, et al. Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin Cancer Res 2003;9:5749–55.
46. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014;510:278–82.
47. Chapuy B, McKeown Michael R, Lin Charles Y, Monti S, Roemer Margaretha GM, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer cell 2013;24:777–90.
48. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478: 529–33.
49. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 2014;514:247–51.
50. Zuber J, Shi JW, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478:524–U124.
51. Delmore Jake E, Issa Ghayas C, Lemieux Madeleine E, Rahl Peter B, Shi J, Jacobs Hannah M, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904–17.
52. Rathert P, Roth M, Neumann T, Muerdter F, Roe J-S, Muhar M, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature 2015;525:543–7.
53. Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Nat Acad Sci 2012;109:19408–13.
54. Thalhammer V, Lopez-Garcia LA, Herrero-Martin D, Hecker R, Laubscher D, Gierisch ME, et al. PLK1 Phosphorylates PAX3–FOXO1, the inhibition of which triggers regression of alveolar rhabdomyosarcoma. Cancer Res 2015;75:98–110.
55. Ciceri P, Müller S, O’Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, et al. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol 2014;10:305–12.
56. Linardic CM.PAX3–FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 2008;270:10–8.
57. Stewart E, Federico S, Karlstrom A, Shelat A, Sablauer A, Pappo A, et al. The childhood solid tumor network: a new resource for the developmental biology and oncology research communities. Devel Biol 2016;411:287–93.
58. Chang W, Brohl A, Patidar R, Sindiri S, Shern JF, Wei JS, et al. Multidimensional clinomics for precision therapy of children and adolescent young adults with relapsed and refractory cancer: a report from the Center for Cancer Research. Clin Cancer Res 2016;22:3810–20.
59. Barski A, Cuddapah S, Cui K, Roh T-Y, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823–37.
60. Jin W, Tang Q, Wan M, Cui K, Zhang Y, Ren G, et al. Genome-wide detection of DNase I hypersensitive sites in single cells and FFPE tissue samples. Nature 2015;528:142–6.